Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Akso Health Group has staged a dramatic reversal in October, climbing 53% over the past month to $1.25, yet the lending market tells a more complicated story underneath the price action.
The most striking feature of the current setup is the borrow market's transformation. Through most of September, availability was essentially uncapped, with virtually no shares being borrowed and the lending pool sitting almost entirely idle. That changed abruptly around September 30, when short interest spiked to roughly 152,000 shares and availability tightened sharply to its 12-month low of 113%. Since then, availability has loosened again to 385%, meaning there are nearly four shares available to borrow for every one currently lent out. But cost to borrow has not followed availability back down. At 16.6%, it is running at about three times the level seen in late August and is near the highest it has been since mid-August. That divergence, ample supply but elevated rental cost, points to brokers pricing in continued volatility rather than a genuine squeeze on stock.
Short interest itself remains too small to drive a narrative. At just 0.013% of the free float, fewer than 72,000 shares are short. The week-on-week change shows shorts pulling back by 53%, reversing a brief October surge. The short score has eased to 51 from around 55 earlier in the week, sitting in the middle of its recent range and not signalling anything particularly directional. The days-to-cover figure from the most recent official FINRA settlement stands at one day, confirming the position is trivially small relative to trading volume.
The Street angle offers limited fresh intelligence here. Analyst coverage data is not current, and the only institutional holder on record is Webao Limited with a 31% stake as of March 2026, data that is now more than six months old and should be treated with caution. The single valuation multiple available, an enterprise value reading anchored to a 2027 fiscal year, cannot be usefully reconciled against a $1.25 stock with no recent earnings guidance, so that figure is omitted. Factor scores paint a mixed picture: the short score rank of 24 (out of 100) suggests shorts are not particularly active relative to peers, but the utilization rank of 18 confirms the borrow market has been unusually quiet for this name. The sector score of 50 puts AHG exactly at the median of its health care distributor group.
Earnings history offers some context for how volatile this stock can be around catalysts. The most recent print in August produced a 7% drop on the day and a 28% slide over the following five days. The July print went the other way, with a 5% gain on the day extending to 10% over the week. With no next earnings date currently scheduled, that binary pattern simply hangs in the background. What is worth watching over the coming days is whether the elevated cost to borrow persists or normalises now that availability has loosened, and whether the modest short interest rebuild seen around September 30 represents a new directional view or was simply opportunistic positioning into the month-end price spike.
See the live data behind this article on ORTEX.
Open AHG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
